Insider Buying: Nautilus Biotechnology (NASDAQ:NAUT) CEO Buys 83,500 Shares of Stock

Key Points

• Nautilus Biotechnology CEO Sujal Patel purchased 83,500 shares at an average price of $0.68, increasing his ownership stake to over 10 million shares valued at approximately $7 million.
• The company's stock saw a decline of 4.4% on Tuesday, trading at $0.67, with a market cap of $84.63 million.
• Analysts expect Nautilus Biotechnology to report -0.57 EPS for the current fiscal year, despite having topped previous earnings estimates.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal Patel purchased 83,500 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were bought at an average cost of $0.68 per share, with a total value of $56,780.00. Following the purchase, the chief executive officer directly owned 10,341,721 shares of the company's stock, valued at approximately $7,032,370.28. This represents a 0.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Nautilus Biotechnology Trading Down 4.4%

Shares of Nautilus Biotechnology stock traded down $0.03 on Tuesday, hitting $0.67. 210,811 shares of the company traded hands, compared to its average volume of 215,461. The company has a market cap of $84.63 million, a PE ratio of -1.29 and a beta of 1.42. Nautilus Biotechnology, Inc. has a 52 week low of $0.62 and a 52 week high of $3.09. The stock's 50 day moving average price is $0.73 and its 200-day moving average price is $0.81.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. As a group, research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of large investors have recently bought and sold shares of NAUT. Barclays PLC grew its holdings in Nautilus Biotechnology by 17.9% in the fourth quarter. Barclays PLC now owns 125,204 shares of the company's stock worth $210,000 after purchasing an additional 19,030 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Nautilus Biotechnology by 11.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company's stock worth $1,294,000 after purchasing an additional 78,367 shares during the last quarter. Hsbc Holdings PLC grew its holdings in Nautilus Biotechnology by 182.5% in the fourth quarter. Hsbc Holdings PLC now owns 55,184 shares of the company's stock worth $92,000 after purchasing an additional 35,650 shares during the last quarter. Jane Street Group LLC grew its holdings in Nautilus Biotechnology by 188.1% in the fourth quarter. Jane Street Group LLC now owns 108,545 shares of the company's stock worth $182,000 after purchasing an additional 70,863 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock worth $83,000 after purchasing an additional 13,363 shares during the last quarter. Institutional investors own 50.71% of the company's stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.